Poxel Announces the Formation of it’s Scientific Advisory Board for Rare Metabolic Diseases

Poxel are a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.

They announced the formation of its Scientific Advisory Board (SAB) for rare metabolic diseases. The new SAB will initially focus on supporting Poxel’s X-linked adrenoleukodystrophy (ALD) program.

The Scientific Advisory Board includes a number of eminent specialists that are good friends to Alex TLC:

• Prof. Florian Eichler, MD
• Prof. Marc Engelen, MD
• Prof. S. Ali Fatemi, MD
• Prof. Stephan Kemp, PhD
• Prof. Fanny Mochel, MD, PhD
• Dr. Jaspreet Singh, PhD
• Prof. Keith Van Haren, MD

 

To read the full announcement: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/202/poxel-announces-the-formation-of-its-scientific-advisory